|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of ACACA mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions decreases expression |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of ADGRE1 mRNA] amlexanox results in decreased expression of ADGRE1 mRNA |
CTD |
PMID:32905826 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
amlexanox affects the reaction [Palmitic Acid affects the expression of ARG1 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of ARG1 protein] |
CTD |
PMID:32905826 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of BAX protein] amlexanox results in decreased expression of BAX protein |
CTD |
PMID:31697998 PMID:32905826 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein] |
CTD |
PMID:31697998 PMID:32905826 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased cleavage of CASP3 protein] |
CTD |
PMID:32905826 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of CD14 mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of CD68 mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of CPT1A mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CXCL2 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CXCL1 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of CYP2E1 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of CYP2E1 protein] |
CTD |
PMID:32905826 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of DGAT1 mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of FASN mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[amlexanox binds to FGF1 protein] inhibits the reaction [cupric chloride results in increased oxidation of FGF1 protein]; amlexanox binds to and results in increased stability of and results in decreased secretion of FGF1 protein; amlexanox inhibits the reaction [FGF1 protein binds to FGF1 protein] |
CTD |
PMID:16300395 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[Acetaminophen co-treated with amlexanox co-treated with dorsomorphin] affects the expression of GCLC mRNA; [Acetaminophen co-treated with amlexanox] affects the expression of GCLC mRNA amlexanox results in increased expression of GCLC mRNA |
CTD |
PMID:31697998 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Acetaminophen co-treated with amlexanox co-treated with dorsomorphin] affects the expression of GCLM mRNA |
CTD |
PMID:31697998 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of GPT protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in increased expression of GPT protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects localization |
ISO |
amlexanox affects the localization of GPX1 mRNA mutant form |
CTD |
PMID:28743738 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[amlexanox co-treated with Acetaminophen] results in increased expression of HMOX1 mRNA; [amlexanox co-treated with Palmitic Acid] results in increased expression of HMOX1 mRNA; amlexanox promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; dorsomorphin inhibits the reaction [[amlexanox co-treated with Acetaminophen] results in increased expression of HMOX1 mRNA] amlexanox results in increased expression of HMOX1 mRNA |
CTD |
PMID:31697998 PMID:32905826 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; amlexanox inhibits the reaction [Paraquat results in increased secretion of IFNB1 protein] |
CTD |
PMID:32763286 PMID:32905826 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases activity multiple interactions |
ISO |
amlexanox results in decreased activity of IKBKE protein amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of IKBKE protein]; amlexanox inhibits the reaction [Palmitic Acid results in increased phosphorylation of IKBKE protein] |
CTD |
PMID:25321315 PMID:31697998 PMID:32905826 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
amlexanox affects the reaction [Palmitic Acid affects the expression of IL10 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of IL10 protein] |
CTD |
PMID:32905826 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of IL1B mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; amlexanox inhibits the reaction [Paraquat results in increased secretion of IL1B protein] |
CTD |
PMID:31697998 PMID:32763286 PMID:32905826 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein] |
CTD |
PMID:31697998 PMID:32905826 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein]; amlexanox inhibits the reaction [Paraquat affects the localization of IRF3 protein] |
CTD |
PMID:32763286 PMID:32905826 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
ISO |
amlexanox results in increased expression of NFE2L2 protein [Acetaminophen co-treated with amlexanox] results in increased expression of NFE2L2 protein; amlexanox inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of NOS2 protein]; mifobate inhibits the reaction [amlexanox inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]] |
CTD |
PMID:32905826 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
dorsomorphin inhibits the reaction [[Acetaminophen co-treated with amlexanox] affects the expression of NQO1 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of PPARA mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in decreased expression of PPARA protein]; amlexanox promotes the reaction [Palmitic Acid results in increased expression of PPARA protein] |
CTD |
PMID:32905826 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
ISO |
amlexanox results in increased phosphorylation of PRKAA1 protein [Acetaminophen co-treated with amlexanox] results in increased phosphorylation of PRKAA1 protein; amlexanox inhibits the reaction [Acetaminophen results in decreased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in decreased phosphorylation of PRKAA1 protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of RELA protein]; amlexanox inhibits the reaction [Paraquat affects the localization of RELA protein] |
CTD |
PMID:31697998 PMID:32763286 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression multiple interactions |
ISO |
amlexanox results in decreased expression of SREBF1 mRNA amlexanox inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 mRNA] |
CTD |
PMID:32905826 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
decreases activity decreases phosphorylation multiple interactions |
ISO |
amlexanox results in decreased activity of TBK1 protein amlexanox results in decreased phosphorylation of TBK1 protein amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of TBK1 protein]; amlexanox inhibits the reaction [Palmitic Acid results in increased phosphorylation of TBK1 protein]; amlexanox inhibits the reaction [Paraquat results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25321315 PMID:31697998 PMID:32763286 PMID:32905826 |
|
NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased expression of TNF mRNA]; amlexanox inhibits the reaction [Palmitic Acid results in increased secretion of TNF protein] |
CTD |
PMID:31697998 PMID:32905826 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Upf1 |
UPF1, RNA helicase and ATPase |
affects localization |
ISO |
amlexanox affects the localization of UPF1 protein |
CTD |
PMID:28743738 |
|
NCBI chr16:19,076,594...19,097,365
Ensembl chr16:19,076,322...19,096,568
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
pyranoprofen results in increased expression of AIFM1 protein |
CTD |
PMID:31765691 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Atm |
ATM serine/threonine kinase |
increases phosphorylation |
ISO |
pyranoprofen results in increased phosphorylation of ATM protein |
CTD |
PMID:31765691 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
pyranoprofen results in increased expression of BAD protein |
CTD |
PMID:31765691 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
pyranoprofen results in increased expression of BAX protein |
CTD |
PMID:31765691 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
pyranoprofen results in decreased expression of BCL2 protein |
CTD |
PMID:31765691 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
pyranoprofen results in decreased expression of BCL2L1 protein |
CTD |
PMID:31765691 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
BDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]] |
CTD |
PMID:16473424 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Casp2 |
caspase 2 |
increases activity |
ISO |
pyranoprofen results in increased activity of CASP2 protein |
CTD |
PMID:31765691 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
pyranoprofen results in increased activity of CASP3 protein |
CTD |
PMID:31765691 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
pyranoprofen results in increased activity of CASP8 protein |
CTD |
PMID:31765691 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
pyranoprofen results in increased activity of CASP9 protein |
CTD |
PMID:31765691 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
pyranoprofen results in increased expression of H2AX protein |
CTD |
PMID:31765691 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
B 4162 inhibits the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]; BDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]; pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium] |
CTD |
PMID:16473424 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
increases expression |
ISO |
pyranoprofen results in increased expression of MLKL protein |
CTD |
PMID:31765691 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity |
ISO |
pyranoprofen results in increased activity of PPARG protein |
CTD |
PMID:12065695 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
pyranoprofen results in increased expression of PTGS2 mRNA |
CTD |
PMID:10594327 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
pyranoprofen results in increased expression of RIPK1 protein |
CTD |
PMID:31765691 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases expression |
ISO |
pyranoprofen results in increased expression of RIPK3 protein |
CTD |
PMID:31765691 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|